Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for entities : Sorrento therapeutics, inc. save search
Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: 3.82%
H: 5.76%
C: 1.04%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -2.03%
H: 3.42%
C: -1.08%
company
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
Published: 2023-09-13 (Crawled : 13:00) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: 1.23%
H: 0.0%
C: -9.72%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -6.99%
H: 39.83%
C: 33.53%
ORMP A | $2.265 2.96% 2.87% 110K
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: -6.17%
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -3.62%
H: 7.95%
C: -8.1%
covid-19 treatment trial
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published: 2023-09-07 (Crawled : 13:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 0.52%
H: 42.58%
C: 36.03%
osteoarthritis positive treatment trial therapeutics results
Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study
Published: 2023-07-05 (Crawled : 13:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 5.1%
H: 1.02%
C: -0.27%
positive treatment results study
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
Published: 2023-06-26 (Crawled : 13:20) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 3.9%
H: 0.0%
C: -3.06%
sti-1558 covid-19 treatment trial
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
Published: 2023-06-13 (Crawled : 13:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.46%
H: 4.85%
C: -1.89%
diagnostic rapid contract platform
Scilex Holding Company provides certain preliminary unaudited financial results for gross and net Sales for the one month ended May 2023, and year-to-date May 2023, based on currently available information
Published: 2023-06-01 (Crawled : 16:00) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: 0.67%
H: 2.67%
C: -1.5%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.83%
H: 0.63%
C: -1.58%
sales one financial results
Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia
Published: 2023-05-31 (Crawled : 19:00) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: 0.67%
H: 2.67%
C: -1.5%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.83%
H: 0.63%
C: -1.58%
ztlido distribution group agreement
Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain
Published: 2023-05-04 (Crawled : 13:00) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: 0.0%
H: 4.91%
C: -4.36%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -0.46%
H: 2.92%
C: -0.5%
sp-103 ztlido back treatment study
Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Possession Financing
Published: 2023-03-29 (Crawled : 18:00) - prnewswire.com
MC | $51.65 1.33% 0.0% 590K
|
Finance
|
| O: 1.57%
H: 0.05%
C: -1.6%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.47%
H: 7.1%
C: 4.48%
approval
Company gets a bit closer to raising $1.1B it needs for mine – Yahoo News
Published: 2023-03-15 (Crawled : 11:00) - spacfeed.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -3.36%
H: 5.63%
C: 0.33%
Company gets a bit closer to raising $1.1B it needs for mine – The Associated Press
Published: 2023-03-15 (Crawled : 11:00) - spacfeed.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -3.36%
H: 5.63%
C: 0.33%
Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment
Published: 2023-03-08 (Crawled : 15:20) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: -0.68%
H: 2.27%
C: -8.52%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -3.06%
H: 1.64%
C: -3.74%
ztlido multi-year commercialization distribution agreement group africa
Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case
Published: 2023-02-21 (Crawled : 00:00) - prnewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: -1.9%
H: 5.12%
C: 3.74%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 11.57%
H: 10.12%
C: -28.53%
approval
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
Published: 2023-02-12 (Crawled : 00:00) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: -20.92%
H: 10.39%
C: -6.84%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -35.61%
H: 9.04%
C: -57.51%
treatment canada migraine
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders
Published: 2023-02-05 (Crawled : 04:20) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
| Email alert
Add to watchlist
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
| Email alert
Add to watchlist
meeting
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)
Published: 2022-12-05 (Crawled : 21:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: -7.02%
imc-001 medical positive
Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA™ Abuse Deterrent Transdermal Technology Patent
Published: 2022-12-01 (Crawled : 12:00) - nutriband.com
NTRB | $3.91 -3.22% -3.32% 26K
|
Manufacturing
|
| O: -1.02%
H: 5.93%
C: 0.52%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -0.77%
H: 2.33%
C: -4.65%
patent transdermal technology
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. with Results To Be Presented at the 2022 American College of Rheumatology Conference
Published: 2022-10-26 (Crawled : 12:00) - biospace.com/
NTRB | $3.91 -3.22% -3.32% 26K
|
Manufacturing
|
| O: 0.24%
H: 10.71%
C: -0.95%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -3.14%
H: 10.39%
C: 3.25%
conference therapeutics study phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.